Toripalimab + axitinib combination approved in China for frontline renal cell carcinoma
The National Medical Products Administration of China has approved toripalimab combined with axitinib (Inlyta) for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic renal cell carcinoma (RCC)
The regulatory decision was supported by data from the phase III RENOTORCH study (NCT04394975) in which the doublet (n = 210) significantly improved blinded independent central review (BICR)–assessed progression-free survival (PFS) vs sunitinib (Sutent) monotherapy (n = 211), at a median of 18.0 months (95% CI, 15.0-not evaluable [NE]) and 9.8 months (95% CI, 8.3-13.8), respectively (stratified, HR; 0.65; 95% CI, 0.49-0.86; P = .0028). The 12-month PFS rates with the doublet and the monotherapy were 62.7% and 45.4%, respectively; at 24 months, these rates were 44.6% and 30.2%, respectively.
“From a global perspective, targeted therapy in combination with immunotherapy has become the standard treatment approach for advanced RCC,” Professor Jun Guo, MD, PhD, from Peking University Cancer Hospital, stated in a press release. “However, no such treatments have been approved in China. The approval of toripalimab’s new indications opens a new chapter in combined targeted therapy and immunotherapy in China, and it will transform current clinical practices for advanced RCC and introduce new treatment options for medium to high-risk patients.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins